3月31日，沪指涨0.38%报3348点，深证成指跌0.01%，创业板指跌0.09%。全天成交1.15万亿元，较前一交易日缩量905亿元，全市场超3800股上涨。板块方 面，医药、可控核聚变板块、超导概念走强，腾讯云概念下挫。 | 代码 | 名称 | 涨幅 | 现价 儿大儿板� | 张停分析 | | --- | --- | --- | --- | --- | | 603011 | 合锁智能 | +10.03% | 14.04 7天5板 | 核聚变+机器人+算力+机器 | | CO33E3 | 和顺石油 | +9.99% | 21.03 5天4板 | 华为超充+加油站+光伏 | | 002549 | 凯美特气 | +10.06% | 9.19 4连板 | 光刻胶+节能环保+氢能源 | | 002923 | 粗都股份 | +10.01% | 16.16 6天3板 | 新型烟草+合成生物+原料药 | | 002808 | ST ロク | +5.16% | 3.26 5天3板 | ST板块+激光光导鼓+信息安 | | 000793 | ST华闻 | +4.95% | 2.33 5天3板 | 被债权人申请重整+海南+文 ...

Group 1 - The core viewpoint indicates that the Chinese stock market is expected to enter a "transformation bull" phase in 2025, driven by market clearing, policy adjustments, and a decline in risk-free interest rates [2] - The China A500 ETF Morgan has seen a recent increase in trading activity, with a transaction volume of 4.05 billion yuan and a turnover rate of 4.4%, reflecting investor interest [1] - The latest scale of the China A500 ETF Morgan reached 9.197 billion yuan, with continuous leverage funding being deployed [1] Group 2 - Morgan Asset Management has launched a series of international "dividend toolbox" funds to provide diversified dividend investment solutions for Chinese investors, covering A-shares, Hong Kong stocks, and Asian markets [2] - The Morgan Asia Dividend Fund focuses on high-dividend assets in the Asia-Pacific region, excluding Japan, and has won the "Golden Bull Overseas Mutual Fund" award for three consecutive years [3] - The Morgan China A50 ETF and the Morgan China A500 ETF have introduced a quarterly dividend mechanism, with the latter being one of the first index funds included in personal pension plans [3] Group 3 - In the new normal of interest rates, Morgan Asset Management aims to help investors seize investment opportunities in relatively "certain" quality assets, leveraging the group's global market insights and research capabilities [4]

Core Viewpoint - The Chinese pharmaceutical sector is experiencing significant growth, as evidenced by the strong performance of the CSI Pharmaceutical 50 Index and its constituent stocks, alongside the notable increase in the Pharmaceutical 50 ETF's scale and shares [1][2][3]. Group 1: Market Performance - As of April 1, 2025, the CSI Pharmaceutical 50 Index rose by 3.24%, with key stocks such as Kelun Pharmaceutical increasing by 9.99% and Kanghong Pharmaceutical by 8.10% [1]. - The Pharmaceutical 50 ETF saw a 2.90% increase, with a latest price of 0.57 yuan and a trading volume of 701.37 million yuan, reflecting a turnover rate of 3.16% [1]. Group 2: Fund Growth Metrics - Over the past year, the Pharmaceutical 50 ETF's scale increased by 12.02 million yuan, ranking it in the top half among comparable funds [2]. - In the last six months, the ETF's shares grew by 17 million, also placing it in the top half of its peers [2]. - Since its inception, the ETF achieved a maximum monthly return of 23.45% and an average monthly return of 4.58% during up months [2]. Group 3: Fee Structure and Valuation - The management fee for the Pharmaceutical 50 ETF is 0.50%, and the custody fee is 0.10%, which are among the lowest in its category [3]. - The latest price-to-earnings ratio (PE-TTM) for the CSI Pharmaceutical 50 Index is 25.39, indicating it is at a historical low compared to the past five years [3]. Group 4: Industry Trends - Recent updates from the National Healthcare Security Administration indicate a rapid entry of newly included domestic innovative drugs into the market, with favorable policies supporting the innovative drug sector [3]. - The number of new drug approvals is at a record high, suggesting a recovery in performance for many companies in the sector in 2024 [3]. Group 5: Top Holdings - As of March 31, 2025, the top ten weighted stocks in the CSI Pharmaceutical 50 Index account for 57.69% of the index, with companies like WuXi AppTec and Heng Rui Medicine being significant contributors [4].

Core Viewpoint - The announcement details the completion of a share buyback plan by a major shareholder, Yaan State-owned Assets Management Co., Ltd., which has increased its stake in Sichuan Kelun Pharmaceutical Co., Ltd. through a combination of loans and self-funding [1][2][3]. Group 1: Shareholder Information - Yaan State-owned Assets Management Co., Ltd. holds 96,983,174 shares, representing 6.07% of the total share capital as of March 27, 2025 [2][3]. - The shareholder's plan involved a minimum investment of 50 million RMB and a maximum of 99 million RMB, with a target share price not exceeding 37.60 RMB per share [1][2]. Group 2: Implementation of the Buyback Plan - From March 1, 2025, to the date of the announcement, Yaan State-owned Assets Management Co., Ltd. has cumulatively acquired 3,182,100 shares, accounting for 0.20% of the total share capital [2][3]. - The total amount spent on the buyback was approximately 98.98 million RMB, which is within the planned investment range [2][3]. Group 3: Regulatory Compliance - The buyback was conducted in compliance with relevant regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [3][4]. - The company confirmed that the buyback will not affect the control of the company or its major shareholders [4].

证券代码：002422 证券简称：科伦药业 公告编号：2025-019 四川科伦药业股份有限公司 关于持股 5%以上股东以金融机构专项增持贷款 和自有资金增持公司股份实施结果的公告 本公司 5%以上股东雅安市国有资产经营有限责任公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1．四川科伦药业股份有限公司（以下简称"公司"、"科伦药业"）于 2025 年 3 月 1 日披露了《关于持股 5%以上股东以金融机构专项增持贷款和自有资金 增持公司股份计划的公告》（公告编号：2025-015）。雅安市国有资产经营有限 责任公司（以下简称"雅安国资公司"）计划于 2025 年 3 月 1 日起六个月内通 过深圳证券交易所允许的方式增持公司股份（拟增持价格不超过 37.60 元/股）， 本次增持金额不低于 5,000 万元人民币（含本数），且不超过 9,900 万元人民币 （含本数）。 2．截至本公告日，持股 5%以上股东雅安国资公司通过深圳证券交易所交易 系统集中竞价交易方式累计增持公司股份 3,182,100 股 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-018 四川科伦药业股份有限公司 公司近日获悉，科伦博泰已于 2025 年 3 月 25 日收到国家药品监督管理局药 品审评中心批准 SKB107 新药临床试验申请的临床试验通知书。 一、药品基本情况 SKB107 是由科伦博泰及西南医大附属医院核医学科共同开发的，以小分子 作为靶向配体，搭配适宜的连接技术、螯合剂和治疗用放射性同位素而组成的新 型 RDC 药物，拟用于治疗晚期实体瘤骨转移。 二、风险提示 创新药物研发过程周期长、环节多、能否开发成功及商业化具有一定的不确 定性，敬请广大投资者谨慎决策，注意防范投资风险。公司将根据后续进展情况 及时履行信息披露义务。 特此公告。 四川科伦药业股份有限公司董事会 2025 年 3 月 26 日 关于子公司放射性核素偶联药物(RDC)SKB107 新药临床试验申请 获国家药品监督管理局批准的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）控股子公司四川科伦博泰 生物医药股份有限公司（以下简称"科伦博泰" ...

四川科伦药业股份有限公司 关于部分回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"），本次注 销部分已回购股票的数量为3,444,001股，占本次注销前总股本1,601,497,373股的 比例为0.22%。本次注销部分回购股份完成后，公司总股本由1,601,497,373股变 更为1,598,053,372股。截至目前，公司已在中国证券登记结算有限责任公司深圳 分公司完成上述部分已回购股票的注销手续。 证券代码：002422 证券简称：科伦药业 公告编号：2025-017 三、公司股本结构变动情况 一、已履行的相关审批流程 （一）公司于2021年7月21日召开的第七届董事会第一次会议审议通过了《关 于回购公司股份的议案》，确定回购的股份将用作员工持股或股权激励计划。但 若公司未能在本次回购完成之后36个月内将全部或部分回购股份用于上述用途， 则尚未使用的股份将在依法履行程序后予以注销。公司在指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）、 ...

Summary of the Conference Call for Kelun Pharmaceutical Company Overview - Kelun Pharmaceutical is a highly regarded company in the capital market, primarily engaged in three main business segments: large-volume parenterals (LVP), active pharmaceutical ingredients (API), and innovative drugs. The company has shifted its focus to innovation since 2012, with Kelun Biotech becoming a leading player in the antibody-drug conjugate (ADC) field globally, backed by major firms like Merck [3][4][6]. Financial Performance - In the first half of 2024, LVP accounted for nearly 40% of total revenue, while API revenue was approximately 3.2 billion RMB, contributing around 28% [3][4]. - Despite the impact of centralized procurement on pricing, the gross margin for LVP remains around 60%, while the gross margin for APIs is 35.3% [4][9]. Market Position and Growth Potential - Kelun holds a leading position in the big data sector with a market share of about 40%. The penetration rate of high-end products is low, indicating significant growth potential in the future [4][5]. - The company expects stable profit trends through 2025, supported by the release of high-end products and cost control measures [4][7]. Innovation and R&D - Kelun Biotech is seen as a key driver of innovation, with domestic commercialization and overseas milestones expected to significantly enhance the company's valuation. The company anticipates that these developments will contribute to revenue and profit growth over the next three years [4][6][10]. - The company invests heavily in R&D, with expenditures nearing 2 billion RMB in 2024, representing about 9% of total revenue. This investment is expected to yield significant results, particularly in big data and innovative drug sectors [11]. Product Development and Market Trends - Kelun Biotech has received approvals for treatment options for triple-negative breast cancer and non-small cell lung cancer, with sales targets set between 800 million to 1 billion RMB for 2025. The collaboration with Merck on ADC drug development holds substantial potential, with a market size expectation of 90 billion RMB [12][20]. - The big data sector is characterized by high concentration, with the top five players holding 80% of the market share. The company is well-positioned to benefit from the ongoing consolidation and increasing demand for essential medications due to an aging population [13]. Competitive Landscape - The company faces challenges from centralized procurement, but it is optimistic about maintaining stable profits through operational optimization and cost reduction [9][10]. - The market for antibiotics, particularly penicillin, is stable with limited new entrants due to regulatory constraints, suggesting a favorable competitive environment for Kelun [16][18]. Future Outlook - The overall assessment indicates that Kelun's traditional business is resilient, while its innovative segments, particularly Kelun Biotech, have substantial untapped potential. The company is projected to generate stable cash flows of approximately 3 billion RMB annually from its big data and API segments, with a significant upside in market valuation expected over the next few years [4][10][20].

四川科伦药业股份有限公司（以下简称"公司"）近日获悉，公司控股子公 司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）靶向人滋养细 胞表面抗原 2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT，前称 SKB264/MK-2870)(佳泰莱®)获国家药品监督管理局(NMPA)批准第二个适应症， 用于治疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)和含铂化疗治疗后 进展的 EGFR 基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC) 成人患者。这是全球首个在肺癌适应症获批上市的 TROP2 ADC 药物。与目前标 准治疗相比，芦康沙妥珠单抗(sac-TMT)显著延长此类患者的总生存获益。 本次批准是基于一项多中心、随机、对照关键临床研究（OptiTROP-Lung03）， 评估芦康沙妥珠单抗(sac-TMT)单一疗法每两周(Q2W)5mg/kg 静脉注射对比多西 他赛用于治疗经 EGFR-TKI 和含铂化疗治疗(序贯或联合)失败后的局部晚期或转 移性 EGFR 突变 NSCLC 患者的有效性和安全性。在预设的期中分析结果显示， 与多西他赛相比，芦康沙妥珠单抗 ...

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) sac-TMT, marking it as the first TROP2 ADC drug approved for lung cancer indications globally [1] Company Summary - Kelong Pharmaceutical's ADC sac-TMT is now approved for a second indication, specifically for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy [1] - The approval signifies a significant advancement in treatment options, as sac-TMT has shown to significantly extend overall survival benefits compared to current standard treatments for this patient population [1]